Triple-negative breast cancer and biomarker-focused treatment selection
Research activity in advanced triple-negative breast cancer centers on refining treatment choice through biomarker assessment, including the BRCA1-like test and response-linked outcomes in measurable and non-measurable disease.
- BRCA1-like testing
- First-line chemotherapy selection
- Progression-free survival
- Platinum-based therapy
The focus includes aligning alkylating agents, platinum agents, and taxane-based therapy with molecular features of the tumor.
HER2-positive breast cancer and neoadjuvant therapy
Studies in HER2-positive breast cancer examine image-guided treatment adaptation and de-escalation strategies in the setting of dual HER2 blockade.
- Trastuzumab and pertuzumab
- Neoadjuvant chemotherapy
- Event-free survival
- Treatment de-escalation
This area reflects interest in balancing anti-HER2 therapy with response-guided reduction of chemotherapy intensity.
Hormone receptor-positive, HER2-negative advanced breast cancer
Clinical research in HR-positive, HER2-negative disease addresses sequential endocrine and targeted approaches across advanced and metastatic settings.
- Aromatase inhibitor-based therapy
- CDK4/6 inhibition
- Fulvestrant
- Progression-free survival
The therapeutic scope includes first-line endocrine strategies and later-line combinations after disease progression.
PIK3CA-mutated breast cancer and targeted endocrine combinations
Work in PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer focuses on targeted treatment after prior endocrine exposure, including patients previously treated with CDK4/6 inhibitors.
- PI3K inhibition
- Alpelisib
- Fulvestrant combination therapy
- Endocrine-resistant disease
This area is centered on mutation-directed treatment for advanced breast cancer after prior systemic therapy.
Previously treated metastatic breast cancer and later-line therapy
Additional research addresses metastatic breast cancer in patients who have already received multiple lines of therapy, with attention to options after prior chemotherapy and endocrine treatment.
- Capecitabine
- Trifluridine/tipiracil
- Later-line treatment
- Disease control
The portfolio includes therapy evaluation in heavily pretreated breast cancer across advanced and metastatic disease states.
